Exenatide
Drug / Medication
An older, first-generation GLP-1 (Gen 1) receptor agonist, part of the triple therapy in the EDI Study and Qatar study, described as effective despite its age.
Mentioned in 3 videos
Save the 3 videos on Exenatide to your own pod.
Sign up free to keep building your knowledge base on Exenatide as more episodes are added.
Videos Mentioning Exenatide
Dave Ricks, CEO of Eli Lilly | The All-In Interview
All-In Podcast
Eli Lilly's first GLP-1 drug, discovered in the saliva of a Gila monster, which helped lower blood sugar and caused weight loss.
The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight
Andrew Huberman
The first GLP-1 drug approved in 2005 for diabetes, derived from Gila monster venom, with a half-life of about 2 hours.
337- Insulin resistance masterclass: The full body impact of metabolic dysfunction, treatment & more
Peter Attia MD
An older, first-generation GLP-1 (Gen 1) receptor agonist, part of the triple therapy in the EDI Study and Qatar study, described as effective despite its age.